Vertex Pharmaceuticals
Analytical review · quarterly report for the period ended June 30, 2026 (Q2 2026)
Bakshi Finance — Family Office | Research Depth: Comprehensive
What this review is based on. Vertex's quarterly report on Form 10-Q for the quarter ended June 30, 2026, filed on August 4, 2026; the results releases for Q4 2025 and Q1 and Q2 2026; the annual report on Form 10-K for 2025; Form 8-K filings on the Crinetics acquisition and on the appointment of a chief financial officer; and the Crinetics Form 8-K reporting completion of the merger. Market data: closing price on October 9, 2026; Bank of Israel representative dollar rate of October 9, 2026.
Company Profile
Vertex Pharmaceuticals is a Boston-based biotechnology company founded in 1989. Its core business is medicines for cystic fibrosis (CF), a serious genetic disease of the lungs and digestive system. The company's medicines do not treat symptoms; they target the defective protein that causes the disease. According to the company, they can treat about 95% of people with CF in its core markets, from one month of age. At the end of 2025 the company had about 6,400 employees.
The company has seven approved medicines: five for CF (TRIKAFTA, sold in Europe as KAFTRIO, and the newer ALYFTREK, alongside three older products); CASGEVY, a CRISPR gene-edited therapy for sickle cell disease and beta thalassemia, developed with CRISPR Therapeutics; and JOURNAVX, an oral non-opioid painkiller for acute pain.
On September 1, 2026 the company completed the acquisition of Crinetics Pharmaceuticals for about $10.0 billion in cash (about $8.8 billion net of Crinetics' cash). Crinetics sells PALSONIFY, an oral treatment for acromegaly, and is developing atumelnant in a Phase 3 trial. The CEO is Dr. Reshma Kewalramani; from January 1, 2027 Jonathan Poole will serve as chief financial officer.
Financial Performance
In the April–June 2026 quarter revenue rose 12% to $3,334 million. U.S. revenue rose 11% and revenue outside the U.S. rose 14%. The company attributes the growth to CF demand, including new patients on ALYFTREK, to higher realized net prices in the U.S., to revenue from CASGEVY and JOURNAVX, and to a favorable currency effect outside the U.S. The company does not publish a split of growth between volume and price.
Operating income rose 8% to $1,247 million, and the operating margin fell from 38.8% to 37.4%. The main reason: selling, general and administrative expenses rose 37%, mainly for the JOURNAVX launch and preparation for the launch of povetacicept in a kidney disease. Research and development expenses rose only 2%. Net income rose 6.5% to $1,100 million, and diluted earnings per share rose 8% to $4.31, helped by a lower share count.
According to company management, 2026 revenue will total $13.1 to $13.2 billion (raised from $12.95 to $13.1 billion), including at least $0.5 billion from non-CF medicines. The guidance excludes Crinetics, and the company said it would update it after the transaction closes.
| $ millions | 2021 | 2022 | 2023 | 2024 | 2025 | 12 mo. to 6/2026 |
|---|---|---|---|---|---|---|
| Revenue | 7,574 | 8,931 | 9,869 | 11,020 | 12,001 | 12,587 |
| Operating income | 2,782 | 4,307 | 3,832 | −233 | 4,173 | 4,777 |
| Net income | 2,342 | 3,322 | 3,620 | −536 | 3,953 | 4,405 |
| Free cash flow | 2,409 | 3,925 | 3,337 | −790 | 3,194 | 3,796 |
| Stock-based compensation | 441 | 491 | 581 | 699 | 686 | 689 |
The 2024 loss reflects $4.4 billion recorded as acquired research and development expense for the purchase of Alpine Immune Sciences (povetacicept). In 2025 a $379 million impairment was recorded on a discontinued diabetes program.
Balance Sheet & Capital
On June 30, 2026 the company held $13,642 million in cash and marketable securities (mainly corporate bonds, U.S. Treasuries and asset-backed securities) and had no financial debt. Shareholders' equity: $20,248 million. Over the past 12 months net interest income totaled $476 million, about 9% of pre-tax income.
What changed after the balance sheet date: in July 2026 the company signed a term loan of up to $4.5 billion ($1 billion for one year, $1 billion for two years and $2.5 billion for three years) and a $500 million revolving facility. According to the Crinetics completion filing, the consideration of about $10.0 billion was funded with cash on hand and borrowings under this loan. The amount actually drawn will be disclosed in the third-quarter report. In the quarterly report the company states that, following the acquisition, it anticipates its net interest income to decrease.
Buybacks: over the past 12 months the company repurchased $2,006 million of its shares. In Q2 it bought 1.03 million shares at an average price of $440. The share count fell 1.2% in a year, to 253.3 million. $2.58 billion remains in the program. The company pays no dividend.
Royalty arbitration: the company pays royalties on CF medicines to the party that acquired the rights from the Cystic Fibrosis Foundation (Royalty Pharma). According to the company, the royalty on TRIKAFTA is 9.33% and on ALYFTREK 4%. Since October 2025 an arbitration has been under way in which Royalty Pharma claims a rate of about 8% on ALYFTREK. Cumulative ALYFTREK revenue to date: $1.8 billion. No accrual has been recorded.
Segments
Vertex reports a single operating segment and discloses revenue by product and by region.
| $ millions | Q2 2025 | Q2 2026 | Change |
|---|---|---|---|
| TRIKAFTA / KAFTRIO | 2,551 | 2,497 | −2% |
| ALYFTREK | 157 | 574 | +266% |
| Legacy CF medicines | 194 | 137 | −29% |
| Total CF | 2,902 | 3,208 | +11% |
| CASGEVY | 30 | 76 | +151% |
| JOURNAVX | 12 | 50 | +313% |
| United States | 1,848 | 2,056 | +11% |
| Europe | 911 | 978 | +7% |
| Rest of world | 206 | 300 | +46% |
The shift within CF: TRIKAFTA and ALYFTREK together brought in $3,071 million, up 13.4%. ALYFTREK's share of the pair reached 18.7%. ALYFTREK is reimbursed in 25 countries, and the company has filed for approval in children aged 2 to 5.
Outside CF: CASGEVY and JOURNAVX together brought in $126 million in the quarter, 3.8% of revenue. CASGEVY rose 78% from the previous quarter and was recently approved in the U.S. for children from age two. About 535 thousand JOURNAVX prescriptions were filled in the quarter, and according to the company about 260 million Americans have reimbursed access to it. Under the note on the CRISPR collaboration, Vertex recorded a $21.8 million credit to cost of sales this quarter as the partner's share of CASGEVY; a credit reflects sharing in the product's net commercial loss.
Competitive Position
In CF, Vertex supplies the medicines that correct the defective protein with almost no competition in the market. Its stated strategy is "serial innovation": replacing each generation of medicines with the next before the protection of the previous one expires. ALYFTREK, taken once a day, is gradually replacing TRIKAFTA, and behind it are three third-generation molecules in early trials; first results for VX-828 were guided for the second half of 2026.
Basic product patent expiry according to the annual report (excluding extensions): TRIKAFTA — 2037 in the U.S. and Europe; ALYFTREK — 2039; JOURNAVX — 2040; CASGEVY — 2035 in the U.S. (regulatory exclusivity). The older medicines expire between 2027 and 2033.
What the filings show on the other side: 96% of revenue comes from a single disease. Revenue flows through distributors: McKesson accounted for 22% of gross product revenue in 2025 and Accredo for 12%. According to the annual report, CF medicines and CASGEVY are currently excluded from the Medicare drug price negotiation program, but Part D changes may have a material impact. This review does not include an assessment of competing technologies under development at other companies.
How to Think About This Company
Vertex is two businesses in one report. The first is the CF franchise: almost all of the revenue, very high margins, and patents to the end of the next decade. The second is a series of investments in new areas — hematology, pain, kidney and now endocrinology — that currently cost more than they bring in. The consolidated report mixes the two, so it helps to read each separately.
CF growth is mainly a shift within the family. TRIKAFTA fell 2% in the quarter; ALYFTREK grew 3.7-fold. The number of patients in the market is limited, so growth comes from younger patients, new countries, longer survival and price. The company cites higher realized net prices in the U.S. and currency among the sources of growth, and does not publish how much of the increase comes from each source.
The shift to ALYFTREK changes the royalty arithmetic. According to the company, the royalty on TRIKAFTA is 9.33% and on ALYFTREK 4%. Every patient who switches improves profitability — if the company's position prevails in arbitration. If Royalty Pharma's position (about 8%) prevails, much of that advantage narrows, although the rate would still be below TRIKAFTA's.
Diversification costs money before it earns it. Selling and commercial expenses rose 47% in the quarter ($124 million), while CASGEVY and JOURNAVX added $84 million of revenue. This is the familiar launch pattern: a sales force is built before the sales arrive. The question is the conversion pace, and it is tested in coming quarters.
Crinetics changes both the balance sheet and the income statement. About $10.0 billion was paid in cash and borrowings. In the first half of 2026 Crinetics recorded an operating loss of $273 million against revenue of $36 million. At the same time Vertex's cash pile, which produced $476 million of interest over 12 months, shrank by about two thirds net of Crinetics' cash. According to company management, the transaction will begin to add to adjusted operating income only in 2029.
Reported and adjusted earnings are relatively close. The main difference between them is stock-based compensation ($170 million in the quarter, about 5.5% of revenue). The third-quarter report, the first to include Crinetics, may change the picture: depending on the accounting treatment, a transaction like this can bring annual amortization of intangible assets or a one-time acquired research and development charge.
Cash flow also benefited from timing this year. Operating cash flow in the first half rose to $2,554 million from $1,892 million. The company attributes part of this to the timing of income tax payments and lower inventory purchases. Taxes paid fell from $698 million to $502 million. For 2025 as a whole, free cash flow was 81% of net income.
The pipeline is long and spread out. Povetacicept for IgA nephropathy awaits an FDA decision by November 30, 2026, and is also being tested in two more diseases. Inaxaplin for a genetic kidney disease, islet cells for type 1 diabetes, myotonic dystrophy and diabetic neuropathic pain are at various stages. That breadth is part of the explanation for research spending of almost $1 billion a quarter.
The multiple reflects the franchise. At a market value of $129 billion, the price equals about 29.7 times net income for the past 12 months and about 34 times free cash flow. When reading the multiple, note that earnings include interest income on a cash pile that has largely been spent, and do not yet include Crinetics' costs.
The framework is meant to organize the questions. It does not decide and does not take part in the decision — the decision belongs to the reader.
This framework is intended to structure analysis, not to produce an investment conclusion.
Risks & Monitoring
Risks arising from the reports
- Concentration: 96% of revenue from a single disease, and two distributors account for about a third of gross revenue.
- Royalty arbitration: a dispute with Royalty Pharma over the ALYFTREK royalty rate (4% vs about 8%), with no accrual.
- Integration and financing: an acquisition of about $10.0 billion, partly funded by a loan with $1 billion due about a year after drawing. The company itself cites the risk of not realizing the benefits of the transaction.
- Regulation and pricing: U.S. growth rests partly on net price. Medicare Part D changes and government pricing programs may have an impact.
- Regulatory decisions: povetacicept (November 30, 2026) and late-stage programs depend on approvals.
- Gene therapy commercialization: CASGEVY requires dedicated treatment centers and a long process; according to the collaboration note, the product is not yet profitable at the commercial level.
Items to monitor in the Q3 report (early November 2026)
| # | Item | Latest reading |
|---|---|---|
| 1 | Crinetics accounting treatment and the loan amount drawn | Not yet reported |
| 2 | Updated 2026 guidance | $13.1–13.2 billion, excluding Crinetics |
| 3 | TRIKAFTA and ALYFTREK combined, year over year | +13.4% in Q2 |
| 4 | Net interest income | $120.6 million in Q2 |
| 5 | CASGEVY, JOURNAVX and PALSONIFY revenue | $76M, $50M and $25M in Q2 |
| 6 | Selling, general and administrative expenses | $582 million (+37%) |
| 7 | FDA decision on povetacicept | Date set by the FDA: November 30, 2026 |
| 8 | ALYFTREK royalty arbitration | Open since October 2025 |
Scenario Framework
The scenarios below are descriptive, not predictive. They contain no prices, no probabilities, and do not rank the outcomes. Their only purpose is to organize the conditions that would need to hold for each state to materialize, so they can be checked against upcoming filings.
Scenarios are descriptive, not predictive.
- If the FDA approves povetacicept and the launch begins to bring in revenue while selling expenses stabilize
- If TRIKAFTA and ALYFTREK keep growing at a double-digit pace even without a currency contribution
- If CASGEVY moves from loss to profit at the commercial level (the partner credit turns into a payment)
- If PALSONIFY revenue grows at a pace that narrows Crinetics' operating loss
- If CF keeps growing at a high single-digit pace, mainly through the shift to ALYFTREK
- If the new medicines keep growing but remain below 10% of revenue
- If interest income declines and Crinetics' losses enter the report, so that earnings per share grow more slowly than revenue
- If the arbitration continues without a ruling
- If the arbitration sets a royalty of about 8% on ALYFTREK, including back payments
- If the FDA does not approve povetacicept or delays the decision, after the sales force has already been built
- If changes in U.S. net prices reduce CF growth
- If the Crinetics accounting brings significant amortization and PALSONIFY revenue grows slowly
Analytical Lens
The six questions below are identical in every company review we publish. They are deliberately open and do not lead to a single conclusion. Their role is to let the reader examine the company along the same six dimensions as any other company.
Key Observations
1. In the April–June 2026 quarter Vertex reported revenue of $3,334 million (+12%), of which $3,208 million came from CF. ALYFTREK brought in $574 million (+266%) and TRIKAFTA $2,497 million (−2%). According to company management, 2026 revenue will total $13.1 to $13.2 billion, excluding Crinetics.
2. Operating income rose 8% to $1,247 million, and the operating margin fell to 37.4% from 38.8%. Selling, general and administrative expenses rose 37%, and research and development expenses 2%.
3. On September 1, 2026 the acquisition of Crinetics was completed for about $10.0 billion, funded with cash and a loan. Before the transaction Vertex held $13.64 billion in cash and investments with no debt. In the first half of 2026 Crinetics recorded an operating loss of $273 million.
4. An arbitration is under way over the ALYFTREK royalty rate: 4% according to Vertex, about 8% according to Royalty Pharma. The date set by the FDA for a decision on povetacicept for IgA nephropathy is November 30, 2026.
Bakshi Finance operates as a Family Office for qualified clients only. Mr. Yaron Bakshi held a licensed investment adviser qualification in Israel during 2008–2023. As of the publication date of this document, the firm does not hold an investment advice, investment marketing or portfolio management licence.
This document is intended for research and professional study purposes only. Nothing herein constitutes a recommendation to buy, sell, hold or carry out any transaction in securities. Nothing herein substitutes for advice that takes into account the data and needs of each person. Every decision is the sole responsibility of the investor.
Past performance is not indicative of future results. Data were drawn from official sources: the quarterly report on Form 10-Q for the quarter ended June 30, 2026 (August 4, 2026), the results releases for Q4 2025 and Q1 and Q2 2026, the annual report on Form 10-K for 2025 (February 13, 2026), and the 2026 filings of Vertex and Crinetics with the U.S. Securities and Exchange Commission. Filings published after this date are not included.
Review for qualified clients โ Family Office
The full analytical review of Vertex Pharmaceuticals (VRTX) for the quarter ended June 2026 is available to Bakshi Finance premium clients.
The review includes a 10-section analysis, "How to Think About This Company" paragraphs, a structured scenario framework, and a six-dimension Analytical Lens.
Bakshi Finance ยท Family Office ยท All rights reserved 2026